Syndax Pharmaceuticals, Inc. (SNDX) Reaches $7.83 After 7.00% Down Move; Shorts at TSUMURA &amp CO ORDINARY SHARES (TSMRF) Lowered By 2.25%

June 4, 2018 - By Stephen Andrade

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Logo

TSUMURA &amp CO ORDINARY SHARES (OTCMKTS:TSMRF) had a decrease of 2.25% in short interest. TSMRF’s SI was 108,700 shares in June as released by FINRA. Its down 2.25% from 111,200 shares previously. It closed at $35.28 lastly. It is down 0.00% since June 4, 2017 and is . It has underperformed by 12.57% the S&P500.

The stock of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a huge mover today! The stock decreased 11.22% or $0.99 during the last trading session, reaching $7.83. About 671,379 shares traded or 78.45% up from the average. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has declined 29.80% since June 4, 2017 and is downtrending. It has underperformed by 42.37% the S&P500.The move comes after 9 months negative chart setup for the $193.45M company. It was reported on Jun, 4 by We have $7.28 PT which if reached, will make NASDAQ:SNDX worth $13.54M less.

Tsumura & Co. engages in the manufacture and sale of pharmaceutical products in Japan, China, and internationally. The company has market cap of $2.74 billion. The firm primarily provides prescription Kampo products covered under the Japanese national health insurance plan, as well as OTC Kampo products. It currently has negative earnings. It is also developing TU-100 (Daikenchuto), which is in Phase II clinical trials for the treatment of irritable bowel syndrome, postoperative ileus, and Crohn's disease in the United States.

More notable recent Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) news were published by: which released: “Syndax: One Step Backward, Two Forward?” on May 23, 2018, also with their article: “Syndax Pharmaceuticals (SNDX) ENCORE 601 Update – Slideshow” published on May 18, 2018, published: “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines” on June 03, 2018. More interesting news about Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) were released by: and their article: “Syndax Pharmaceuticals: Elucidating The Results Of The Phase 2 ENCORE 601 Trial” published on May 28, 2018 as well as‘s news article titled: “Syndax and Nektar Therapeutics team up in study of doublet therapy for advanced melanoma” with publication date: May 30, 2018.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Ratings Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: